DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
58 hedge funds and large institutions have $18M invested in DMK Pharmaceuticals Corporation Common Stock in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
26% more funds holding
Funds holding: 46 → 58 (+12)
32% less call options, than puts
Call options by funds: $504K | Put options by funds: $737K
38% less capital invested
Capital invested by funds: $29M → $18M (-$11M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRF
B. Riley Financial
Los Angeles,
California
|
+$1.09M |
| 2 |
Barclays
London,
United Kingdom
|
+$498K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$497K |
| 4 |
VF
Virtu Financial
New York
|
+$472K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$465K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$10.1M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$1.94M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$524K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
-$229K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$164K |
DMK Hedge Fund Activity: Q4 2017 in Review
58 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q4 2017, worth a combined $18M — down 38% from $29M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DMK positions and 6 closed out — a net gain of 12 holders — while 20 added to existing stakes and 10 trimmed.
The largest buyer was B. Riley Financial, opening a new position worth an estimated $1.09M. The largest seller was Sio Capital Management, exiting entirely with an estimated $10.1M sold.
- 58 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q4 2017, up from 46 in Q3 2017.
- Funds reported $18M of DMK Pharmaceuticals Corporation Common Stock stock for Q4 2017, down 38% quarter-over-quarter.
- 18 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q4 2017 and 6 closed out, a net change of +12 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q4 2017 was B. Riley Financial, an estimated $1.09M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q4 2017 was Sio Capital Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q4 2017.